Department of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, United States.
Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, United States; Department of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, United States.
Psychiatry Res. 2023 Nov;329:115524. doi: 10.1016/j.psychres.2023.115524. Epub 2023 Oct 4.
Methamphetamine use is a growing public health concern nationwide. Suicide is the second leading cause of death in 2019 for US citizens aged 10-14 years and 25-34 years and is also a significant public health concern. Understanding the intersection of methamphetamine use and suicidal ideation (SI) is necessary to develop public health and policy solutions that mitigate these ongoing severe public health issues.
Our objective was to examine SI in methamphetamine users to allow us to determine prevalence and trends by age, sex, race, and geographical region.
DESIGN, SETTINGS, AND PARTICIPANTS: Using data collected between 2008 and 2019 from the National Inpatient Sample (NIS) database, we identified hospital admissions (HA) of patients ≥18 years of age with a primary or secondary diagnosis of SI who were also diagnosed as methamphetamine users. Those who used other substances with methamphetamine were excluded from the analysis.
To determine the trend and prevalence of hospital admissions due to SI and SI among methamphetamine users, we used trend weights to calculate the national estimates and performed design-based analysis to account for complex survey design and sampling weights on data collected between 2008 and 2019 in the US.
The prevalence ratio (PR) of hospitalizations with concurrent SI and methamphetamine use increased 16-fold from 2008 to 2019. The most significant increase occurred between 2015 and 2016; the PR doubled from 6.07 to 12.14. The PR of hospitalizations with concurrent SI and methamphetamine use was highest in patients aged 26-40 (49.08%) and 41-64 (28.49%). Patients aged 41-64 showed the most significant increase from 2008 to 2019 (15.8-fold). While non-Hispanic White patients comprised most of these hospitalizations (77.02%), non-Hispanic Black patients showed the highest proportional increase (39.1-fold). The Southern and Western regions in the US showed the highest PR for these hospitalizations (34.86% and 34.31%, respectively).
Our findings indicate that SI in methamphetamine users has been increasing for some time and is likely to grow. In addition, our results suggest that these patients are demographically different. Both conditions are associated with a lesser likelihood of seeking and receiving care. Therefore, when addressing increased SI or methamphetamine use, learning more about patients who share both conditions is necessary to ensure proper care.
甲基苯丙胺的使用是全美日益严重的公共卫生问题。自杀是美国 10-14 岁和 25-34 岁人群 2019 年的第二大死因,也是一个重大的公共卫生问题。了解甲基苯丙胺使用和自杀意念(SI)之间的交集对于制定减轻这些持续严重公共卫生问题的公共卫生和政策解决方案是必要的。
我们的目的是研究甲基苯丙胺使用者的 SI,以便我们能够确定按年龄、性别、种族和地理位置划分的患病率和趋势。
设计、设置和参与者:我们使用 2008 年至 2019 年期间从国家住院患者样本(NIS)数据库中收集的数据,确定≥18 岁的因 SI 而住院的患者的住院治疗(HA),并被诊断为甲基苯丙胺使用者。那些同时使用其他物质和甲基苯丙胺的人被排除在分析之外。
为了确定 SI 和同时使用甲基苯丙胺导致的住院治疗的趋势和患病率,我们使用趋势权重计算了全国估计数,并进行了基于设计的分析,以考虑 2008 年至 2019 年期间在美国收集的数据的复杂调查设计和抽样权重。
2008 年至 2019 年,同时患有 SI 和甲基苯丙胺的住院患者的患病率比值(PR)增加了 16 倍。最大的增长发生在 2015 年至 2016 年之间;PR 从 6.07 翻了一番至 12.14。同时患有 SI 和甲基苯丙胺的住院患者中,年龄在 26-40 岁(49.08%)和 41-64 岁(28.49%)的患者 PR 最高。年龄在 41-64 岁的患者从 2008 年至 2019 年的增长最为显著(15.8 倍)。尽管这些住院患者中大多数是西班牙裔白人(77.02%),但西班牙裔黑人患者的比例增长最高(39.1 倍)。美国南部和西部地区的这些住院患者的 PR 最高(分别为 34.86%和 34.31%)。
我们的研究结果表明,甲基苯丙胺使用者的 SI 已经有一段时间呈上升趋势,而且可能还会继续增长。此外,我们的研究结果表明,这些患者在人口统计学上存在差异。这两种情况都与寻求和接受护理的可能性降低有关。因此,在解决自杀意念或甲基苯丙胺使用增加的问题时,了解同时患有这两种疾病的患者的情况是必要的,以确保提供适当的护理。